Search results
FDA Approves Geron's First Commercial Drug, Competes With Bristol Myers Squibb's Blood Cancer Drug
Benzinga via AOL· 20 hours agoOn Thursday, the FDA approved Geron Corporation's (NASDAQ:GERN) Rytelo (imetelstat) for adult...
FDA approves first RSV vaccine for at-risk adults in their 50s
CBS News· 12 hours agoThe Food and Drug Administration has approved giving GSK's vaccine for respiratory syncytial virus...
Is Geron Stock a Buy Following Its First New Drug Approval? | The Motley Fool
The Motley Fool· 1 hour agoShares of Geron (GERN 18.00%) finished the week ended June 7 about 32% higher. On June 6, the U.S. Food and Drug Administration (FDA) approved Geron's first ...
FDA approves Geron’s RYTELO for MDS associated anaemia
Pharmaceutical Technology via Yahoo Finance· 1 day ago"FDA approves Geron’s RYTELO for MDS associated anaemia" was originally created and published by...
FDA approves GSK's RSV vaccine for high-risk adults ages 50 to 59, expanding shot's reach
CNBC· 13 hours agoThe shot, called Arexvy, is the first vaccine cleared by the FDA to protect that population from...
FDA approves new method to ease back pain
WINK TV Southwest Florida· 16 hours agoThe FDA has approved a new way to ease back pain.
US FDA expands GSK's RSV vaccine approval to adults aged 50 to 59
Reuters via Yahoo News· 14 hours ago(Reuters) -The U.S. Food and Drug Administration approved the expanded use of GSK's respiratory...
US FDA staff raise no major concerns about Eli Lilly Alzheimer's drug
Reuters via Yahoo News· 2 days agoAn FDA analysis of trial data for Eli Lilly's experimental Alzheimer's drug donanemab released on...
FDA Approves Moderna’s mRESVIA Vaccine | JD Supra
JD Supra· 1 day agoOn May 31, 2024, Moderna announced that the FDA has approved its respiratory syncytial virus vaccine (“RSV”), mRESVIA (mRNA-1345). The vaccine...
The FDA Could, Finally, Approve Novavax's Covid Vaccine — Is Novavax Stock A Buy?
Investor's Business Daily· 18 hours agoThis is appealing to people who are uneasy with the newer mRNA technology. But the competitor...